News & Updates
Filter by Specialty:
Silymarin reduces lesions, pain in women with endometriosis
Among women suffering from endometriosis, treatment with silymarin leads to lowered interleukin (IL)-6 concentrations, smaller endometrioma lesions, and eased pain, a recent study has found.
Silymarin reduces lesions, pain in women with endometriosis
26 Oct 2022Psychotic disorders a potentially modifiable risk factor for dementia
Individuals with nonaffective psychotic disorders appear to have a twofold higher risk of developing subsequent dementia compared with those who do not have such disorders, as reported in a recent study.
Psychotic disorders a potentially modifiable risk factor for dementia
25 Oct 2022Singaporeans’ affair with Western-style fast food: Unhealthy and possibly deadly
A diet heavy in Western-style fast food is known to make people fat and unhealthy, and a recent study quantifies its toll in an Eastern population, particularly Singaporeans: Frequent intake puts one at risk of developing type 2 diabetes (T2D) and dying from coronary heart disease (CHD).
Singaporeans’ affair with Western-style fast food: Unhealthy and possibly deadly
25 Oct 2022Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
In the 6-year follow-up of the ECHELON-1 trial, a combination of the CD30-directed ADC* brentuximab vedotin and a chemotherapy (CT) regimen comprising doxorubicin, vinblastine, and dacarbazine (A+AVD), showed a survival advantage over a combination comprising the same CT regimen plus bleomycin (ABVD) in patients with previously untreated stage III or IV Hodgkin’s lymphoma (HL).
Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
25 Oct 2022Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
Among people living with HIV (PLHIV), immunization with a hepatitis B surface antigen (HBsAg)-based vaccine adjuvanted with a toll-like receptor (TLR)-9 agonist can induce a 100-percent seroprotection rate, according to a study presented at the recently concluded Virtual ID Week 2022.